The first-in-human clinical trial assessing the safety and tolerability of Miltuximab (MIL-38) — a radiolabeled antibody designed to image prostate, bladder, and pancreatic cancer — is proceeding to its second part, according to Minomic International. Miltuximab is a chimeric version of Minomic’s MIL-38 antibody, linked to the radioactive isotope Gallium-67. A chimeric antibody is one that includes human … Continue reading Trial of Miltuximab in Prostate, Other Cancers Gets Nod to Enroll Additional Patients